TAVR devices have undergone continuous advancements, significantly reducing early-generation periprocedural complications.
Novel TAVR observation in early human data is hypothesis-generating; leaves open need for confirmatory trials before any practice consideration.
Transcatheter aortic valve replacement (TAVR) has revolutionized the management of aortic stenosis (AS), offering a less-invasive alternative to surgical aortic valve replacement. Since its approval in the United States in 2011 for patients with severe AS at high or extreme surgical risk, TAVR has undergone continuous advancements. Early-generation TAVR devices prioritized reducing periprocedural complications like paravalvular leak, stroke, and major vascular complications. These complications have become increasingly uncommon due to iterative improvements in device design.
No takes yet. Share an insight, caveat, or question.
Sethi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: